These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32431492)

  • 1. Factors Driving Patient Preferences for Growth Hormone Deficiency (GHD) Injection Regimen and Injection Device Features: A Discrete Choice Experiment.
    McNamara M; Turner-Bowker DM; Westhead H; Yaworsky A; Palladino A; Gross H; Pleil A; Loftus J
    Patient Prefer Adherence; 2020; 14():781-793. PubMed ID: 32431492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Psychometric Evaluation of the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) to Assess Growth Hormone Injection Burden in Children and Adults.
    Turner-Bowker DM; Yaworsky A; Palladino A; Lamoureux RE; Kelly M; Love E; Pleil AM; Shields A; Loftus J
    Patient; 2020 Jun; 13(3):289-306. PubMed ID: 31956960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient preferences for growth hormone treatment in Japanese children.
    Tanaka T; Sato T; Yuasa A; Akiyama T; Tawseef A
    Pediatr Int; 2021 Oct; 63(10):1185-1191. PubMed ID: 33930225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine.
    Seo J; Tervonen T; Ueda K; Zhang D; Danno D; Tockhorn-Heidenreich A
    Neurol Ther; 2023 Apr; 12(2):651-668. PubMed ID: 36848008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and meeting the needs of those using growth hormone injection devices.
    Dumas H; Panayiotopoulos P; Parker D; Pongpairochana V
    BMC Endocr Disord; 2006 Oct; 6():5. PubMed ID: 17034628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the TUITEK
    Assefi AR; Graham S; Crespo ML; Debicki M; Reston J; Gonzalez J; Jheeta A; Koledova E
    Front Endocrinol (Lausanne); 2023; 14():1129385. PubMed ID: 37091843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China.
    Wei Y; Zhao J; Ming J; Zhang X; Chen Y
    Patient Prefer Adherence; 2022; 16():2387-2398. PubMed ID: 36068820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
    Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
    J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment.
    Ng-Mak D; Poon JL; Roberts L; Kleinman L; Revicki DA; Rajagopalan K
    Patient Prefer Adherence; 2018; 12():35-44. PubMed ID: 29343947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
    Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
    J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS).
    Blanco-López A; Antillón-Ferreira C; Saavedra-Castillo E; Barrientos-Pérez M; Rivero-Escalante H; Flores-Caloca O; Calzada-León R; Rosas-Guerra CC; Koledova E; Chiquete E; Ayala-Estrada A
    J Endocrinol Invest; 2020 Oct; 43(10):1447-1452. PubMed ID: 32239476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
    Thieu VT; Robinson S; Kennedy-Martin T; Boye KS; Garcia-Perez LE
    Patient Prefer Adherence; 2019; 13():561-576. PubMed ID: 31114170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
    van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
    Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.
    Grumbach MM; Bin-Abbas BS; Kaplan SL
    Horm Res; 1998; 49 Suppl 2():41-57. PubMed ID: 9730672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries.
    Lo SH; Lawrence C; Martí Y; Café A; Lloyd AJ
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):103-115. PubMed ID: 34897574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new pen device for injection of recombinant human growth hormone: a convenience, functionality and usability evaluation study.
    Sauer M; Abbotts C
    Patient Prefer Adherence; 2018; 12():27-34. PubMed ID: 29343946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.